title: [Use of dexamethasone in treatment of high- and low-grade non-Hodgkin's lymphoma].
abstract: Since it exerts a stronger antitumor action than predinisolone, dexamethasone was used for therapy of patients with non-Hodgkin's lymphoma refractory to CHOP. All patients (66), resistant to CHOP, suffered bone marrow involvement. Dexamethasone pulsed therapy was given to 45 patients, with 21 COP-BLAM or ASHAP, MAD, Dexa-BEAM treated in control. Median response duration in high- and low-grade non-Hodgkin's lymphoma groups was 2 and 12 months, respectively.
authors.forename: Iu A
authors.initials: IuA
authors.lastname: Alekseeva
authors.forename: A Iu
authors.initials: AIu
authors.lastname: Zaritskiĭ
authors.forename: N V
authors.initials: NV
authors.lastname: Medvedeva
authors.forename: N B
authors.initials: NB
authors.lastname: Mikhaĭlova
authors.forename: L S
authors.initials: LS
authors.lastname: Zubarovskaia
authors.forename: B V
authors.initials: BV
authors.lastname: Afanas'ev
mesh_terms: D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002330:Carmustine / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use*; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology*; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D003561:Cytarabine; D005047:Etoposide; D003907:Dexamethasone; D008558:Melphalan; D002330:Carmustine